229 related articles for article (PubMed ID: 31768803)
21. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
Tan L; Tang Y; Peng W; Mathew BS; Qin W
Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
[TBL] [Abstract][Full Text] [Related]
23. Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
Ye Z; Zhang L; Xu L; Shi W; Hu H; Shi X; Zhong W; Hou S; Yan H; Zhang B; Xia Y; Wang W; Feng Z; Wang L; Liang Y
Nephrology (Carlton); 2014 Jan; 19(1):40-6. PubMed ID: 24191893
[TBL] [Abstract][Full Text] [Related]
24. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
[TBL] [Abstract][Full Text] [Related]
25. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Park HC; Xu ZG; Choi S; Goo YS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Nephrol Dial Transplant; 2003 Jun; 18(6):1115-21. PubMed ID: 12748343
[TBL] [Abstract][Full Text] [Related]
26. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
[TBL] [Abstract][Full Text] [Related]
27. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
Yang X; Ma F; Bai M; Wang Y; Jia Q; Dong R; Liu C; Sun S
Ren Fail; 2021 Aug; 43(1):1180-1187. PubMed ID: 34376108
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy
.
Ihm HS; Lee JY; Hwang HS; Kim YG; Moon JY; Lee SH; Jeong KH; Lee TW; Ihm CG
Clin Nephrol; 2019 Sep; 92(3):131-140. PubMed ID: 31232271
[TBL] [Abstract][Full Text] [Related]
30. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
Manno C; Gesualdo L; D'Altri C; Rossini M; Grandaliano G; Schena FP
J Nephrol; 2001; 14(4):248-52. PubMed ID: 11506246
[TBL] [Abstract][Full Text] [Related]
31. Sodium-sensitive variability of the antiproteinuric efficacy of RAS inhibitors in outpatients with IgA nephropathy.
Suzuki T; Miyazaki Y; Shimizu A; Ito Y; Okonogi H; Ogura M; Utsunomiya Y; Kawamura T; Hosoya T
Clin Nephrol; 2009 Oct; 72(4):274-85. PubMed ID: 19825333
[TBL] [Abstract][Full Text] [Related]
32. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
Tang Y; He H; Sun W; Hu P; Chen X; Xu X
Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
[TBL] [Abstract][Full Text] [Related]
33. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
[TBL] [Abstract][Full Text] [Related]
34. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
[TBL] [Abstract][Full Text] [Related]
35. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
Rauen T; Eitner F; Fitzner C; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JF; Hilgers RD; Floege J;
N Engl J Med; 2015 Dec; 373(23):2225-36. PubMed ID: 26630142
[TBL] [Abstract][Full Text] [Related]
36. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
Eitner F; Ackermann D; Hilgers RD; Floege J
J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D deficiency may predict a poorer outcome of IgA nephropathy.
Li XH; Huang XP; Pan L; Wang CY; Qin J; Nong FW; Luo YZ; Wu Y; Huang YM; Peng X; Yang ZH; Liao YH
BMC Nephrol; 2016 Nov; 17(1):164. PubMed ID: 27806690
[TBL] [Abstract][Full Text] [Related]
39. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
40. Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
Gan L; Li X; Zhu M; Chen C; Luo H; Zhou Q
Ren Fail; 2018 Nov; 40(1):364-370. PubMed ID: 29708439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
